Article

Induced ERBB response and standing FAK dependency nominate separable KRAS-combination hypotheses in pancreatic cancer

2026-07-10

Abstract excerpt

<h4>Summary</h4> Pancreatic ductal adenocarcinoma (PDAC) is driven by oncogenic KRAS in roughly 90% of cases, and KRAS-pathway inhibition has finally become clinically active. Durable benefit, however, will require identifying the adaptive and baseline vulnerabilities that shape response to KRAS inhibition. Two resistance mechanisms have been proposed separately in the literature — receptor-tyrosine-kinase bypass...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f5fbdf16-73ad-52d7-a595-9fb76e67b786
DOI: 10.64898/2026.07.09.737590

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Induced ERBB response and standing FAK dependency nominate separable KRAS-combination hypotheses in pancreatic cancerDOI 10.64898/2026.07.09.737590Read

Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic CancerSemantic proximity Read

Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbationsSemantic proximity Read

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read

Pharmacologically targeting KRAS <sup>G12D</sup> in PDAC models: tumor cell intrinsic and extrinsic impactSemantic proximity Read

Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.Semantic proximity Read

Kinome state is predictive of cell viability in pancreatic cancer tumor and stroma cell linesSemantic proximity Read

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read

Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition.Semantic proximity Read

Durability of Kinase-Directed Therapies—A Network Perspective on Response and ResistanceSemantic proximity Read

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapySemantic proximity Read

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistanceSemantic proximity Read

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in <i>KRAS</i> -Mutant CancersSemantic proximity Read